Lymphotoxin alpha Beta and LIGHT cytokine systems
Lymphotoxin alpha Beta and LIGHT cytokine systems
批准号:
8206586
负责人:
Carl F Ware
金额:
$46.8万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-08-01 至 2013-12-31
关键词:
AddressAffectAgonistAntigen-Presenting CellsAntigensAreaAscaridilAutoimmune DiseasesAutoimmunityB cell differentiationB-LymphocytesBindingCellsCessation of lifeCommunicable DiseasesCommunicationCytokine Network PathwayCytomegalovirusDendritic CellsDevelopmentDiseaseEnzymesExperimental ModelsFamilyFundingFunding MechanismsFutureGenesGoalsGrantHerpesviridaeHomeostasisHost DefenseHumanImmuneImmune ToleranceImmune responseImmune systemImmunityInflammationInflammatoryInterferon Type IInternationalIntestinesInvestigationLigandsLightLymphocyteLymphoidMediatingMembraneModelingMolecularMucosal ImmunityMusOrganOrthologous GenePathway interactionsPatientsPeripheralPhysiologyPositioning AttributeProcessProgress ReportsReceptor SignalingRegulationReportingResearchRoleSignal PathwaySignal TransductionSyndromeSystemT-Cell ActivationT-LymphocyteTumor Necrosis Factor ReceptorTumor Necrosis Factor-BetaTumor Necrosis Factor-alphaVariantViral PathogenesisWorkattenuationbasecytokineexpression cloningherpesvirus entry mediatorinsightintercellular communicationmembernovelprogramsreceptorresponsetrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
T cell activation and differentiation is dependent on TCR engagement of antigen and cooperating signals
provided by several distinct receptor-ligand systems. The herpesvirus entry mediator (HVEM), a TNF
superfamily member, engages LIGHT initiating costimulatory signals to T cells, yet HVEM also engages B
and T lymphocyte attenuator (BTLA), an Ig superfamily member that provides an inhibitory signal to T cells.
Substantial progress indicates that HVEM acts as a molecular switch between positive and inhibitory
cosignaling in T cells. Moreover, the HVEM-BTLA system counter acts the closely related LTa(3-LT|3R
system, which together regulates the homeostasis and expansion of specific subsets of dendritic cells in
lymphoid organs. Thus understanding the regulatory mechanisms of this cytokine network should provide
new insight into controlling immune responses. We found that LIGHT in either its membrane or soluble
position modifies the binding of HVEM to BTLA, thus the mechanisms controlling the cellular
compartmentalization of LIGHT may influence inhibitory signaling by BTLA. We propose to examine how
various forms of LIGHT modulate the HVEM-BTLA interaction. Specifically how soluble ligands and
polymorphic variants of LIGHT modify activation of BTLA. In addition, polymorphic variants of human LIGHT
will be examined for their influence on LIGHT shedding and the enzyme involved in cleavage of membrane
LIGHT will be identified using an expression cloning strategy. We will explore whether analogous pathways
to HVEM-BTLA exist for other TNFR containing the conserved BTLA binding domain. HVEM-BTLA acts at a
postmitotic step to limit dendritic cell expansion. The attenuation of death receptor signaling will be examined
as one mechanism mediating the inhibitory affect of HVEM-BTLA on dendritic cell homeostasis using mouse
and human models. These plans will provide a mechanistic understanding of how LTap and LIGHT signals
are integrated to orchestrate intercellular communication between T lymphocytes and dendritic cells during
immune responses.
Lay summary: Our research identified an important set of molecules, termed cytokines, that control how
immune cells communicate with each other. We demonstrated that altering the activity of these molecules
changes the responses of cells. This research provides a new opportunity to modify the function of the
immune system in autoimmune and infectious diseases
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1136/gutjnl-2014-308810
发表时间:
2016-10
期刊:
Gut
影响因子:
24.5
作者:
[Scarzello AJ, Jiang Q, Back T, Dang H, Hodge D, Hanson C, Subleski J, Weiss JM, Stauffer JK, Chaisaingmongkol J, Rabibhadana S, Ruchirawat M, Ortaldo J, Wang XW, Norris PS, Ware CF, Wiltrout RH]
通讯作者:
Wiltrout RH
DOI:
10.1371/journal.ppat.1000650
发表时间:
2009-11
期刊:
PLoS pathogens
影响因子:
6.7
作者:
[Nakhaei P, Mesplede T, Solis M, Sun Q, Zhao T, Yang L, Chuang TH, Ware CF, Lin R, Hiscott J]
通讯作者:
Hiscott J
ICOS, CD40, and lymphotoxin beta receptors signal sequentially and interdependently to initiate a germinal center reaction.
ICOS、CD40 和淋巴毒素 β 受体依次且相互依赖地发出信号以启动生发中心反应。
DOI:
10.4049/jimmunol.180.4.2284
发表时间:
2008
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Vu,Frances, Dianzani,Umberto, Ware,CarlF, Mak,Tak, Gommerman,JenniferL]
通讯作者:
Gommerman,JenniferL
Overriding the Immune Evasion Tactics of Coronavirus
-
批准号:10237419
-
项目类别:
-
资助金额:$61.8万
-
财政年份:2020
-
负责人:Carl F Ware
-
依托单位:
Overriding the Immune Evasion Tactics of Coronavirus
-
批准号:10671613
-
项目类别:
-
资助金额:$60.16万
-
财政年份:2020
-
负责人:Carl F Ware
-
依托单位:
Overriding the Immune Evasion Tactics of Coronavirus
-
批准号:10188930
-
项目类别:
-
资助金额:$61.8万
-
财政年份:2020
-
负责人:Carl F Ware
-
依托单位:
Overriding the Immune Evasion Tactics of Coronavirus
-
批准号:10454292
-
项目类别:
-
资助金额:$60.16万
-
财政年份:2020
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA Pathway in Lymphoma
-
批准号:8700133
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2012
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA Pathway in Lymphoma
-
批准号:8534744
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2012
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA Pathway in Lymphoma
-
批准号:8370219
-
项目类别:
-
资助金额:$40.46万
-
财政年份:2012
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA Pathway in Lymphoma
-
批准号:9081538
-
项目类别:
-
资助金额:$40.46万
-
财政年份:2012
-
负责人:Carl F Ware
-
依托单位:
MODULATING LYMPHOTOXINS IN PRIMATES FOR VIRAL DEFENSES
-
批准号:8357268
-
项目类别:
-
资助金额:$19.14万
-
财政年份:2011
-
负责人:Carl F Ware
-
依托单位:
Human Lymphoid Tissue Inducers
-
批准号:8136779
-
项目类别:
-
资助金额:$17.19万
-
财政年份:2010
-
负责人:Carl F Ware
-
依托单位:
MODULATING LYMPHOTOXINS IN PRIMATES FOR VIRAL DEFENSES
-
批准号:8172541
-
项目类别:
-
资助金额:$15.21万
-
财政年份:2010
-
负责人:Carl F Ware
-
依托单位:
Human Lymphoid Tissue Inducers
-
批准号:7874791
-
项目类别:
-
资助金额:$6.62万
-
财政年份:2010
-
负责人:Carl F Ware
-
依托单位:
Human Lymphoid Tissue Inducers
-
批准号:8020148
-
项目类别:
-
资助金额:$28.36万
-
财政年份:2010
-
负责人:Carl F Ware
-
依托单位:
MODULATING LYMPHOTOXINS IN PRIMATES FOR VIRAL DEFENSES
-
批准号:7959029
-
项目类别:
-
资助金额:$14.66万
-
财政年份:2009
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in inflammation
-
批准号:8143923
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in Inflammation
-
批准号:8890072
-
项目类别:
-
资助金额:$48.0万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in inflammation
-
批准号:7848859
-
项目类别:
-
资助金额:$10.63万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in inflammation
-
批准号:7413616
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in inflammation
-
批准号:7264400
-
项目类别:
-
资助金额:$47.45万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in Inflammation
-
批准号:8507113
-
项目类别:
-
资助金额:$47.35万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
海外基金